Why every GLP-1 provider suddenly sells 'microdosing'

It is marketed as a gentler, smarter, cheaper way to take a GLP-1. It is also the only remaining way a compounding pharmacy can legally make one.

Start with the timeline

Compounded GLP-1 existed because of one legal fact: while a drug is on the FDA shortage list, the bar against compounding an 'essentially a copy' product is lifted. Both shortages ended.

By May 2025, shortage-based compounding of semaglutide and tirzepatide was outside enforcement discretion for every class of compounder. The courts upheld the FDA. The legal foundation of a multi-billion-dollar industry was gone.

And yet the industry did not disappear. It pivoted — to 'personalized dosing' and 'microdosing'.

The rule that explains the pivot

One narrow route survived. Under section 503A, a compounded product is not 'essentially a copy' of an approved drug if the prescriber determines, and documents on the prescription, that the change produces a significant clinical difference for that individual patient.

A dose that is not 'the same, similar, or easily substitutable' for an approved strength is a dose that falls outside the copy definition. A 1mg weekly tirzepatide microdose — against approved strengths of 2.5 through 15mg — is exactly such a dose.

That is the mechanism. Microdosing is not primarily a clinical innovation that happened to arrive in 2025. It is the legal structure that lets a 503A pharmacy keep compounding these molecules at all, and its timing tracks the end of enforcement discretion almost to the month.

Two things are true at once

Honest coverage has to hold both.

Microdosing has a real clinical rationale for some patients. People who cannot tolerate full-dose escalation. People maintaining after reaching goal weight. People for whom cost is the binding constraint. A clinician-directed low dose is a legitimate choice for them, and this article is not an argument against it.

And it is also a regulatory workaround. Both of these are true simultaneously, and a provider telling you only the first half is telling you half a story.

What it costs you in effect

A microdose sits below every dose studied in the trials. SURMOUNT-1 tested 5, 10 and 15mg and found 15.0%, 19.5% and 20.9% mean weight reduction. A 1mg microdose has no equivalent trial behind it and should be expected to produce a smaller effect.

That is not a criticism — it is arithmetic. But anyone presenting a microdose programme as a cheaper route to the SURMOUNT headline number is misleading you, and that framing is everywhere.

What to ask

One question cuts through all of it: why was this specific dose chosen for me?

If the answer is about your tolerance, your goals, your history — good. If the answer is vague, or if the same 'personalized' dose is what everyone gets, then the personalisation may be doing regulatory work rather than clinical work. Ask directly whether the dose was selected partly to keep the product outside the 'essentially a copy' rule. The reaction to that question is informative.

Limitations of this analysis

Every page on this site should tell you where it stops being reliable. This one stops here.

Prices decay quickly. This is the fastest-moving data we publish. Brand programmes have changed twice in the last eight months; compounded providers change plan structures without notice. Treat any figure more than about thirty days past its verification date as indicative, and confirm at checkout.

Competitor pricing is reported, not captured by us. We hold dated captures for brand pricing and for NexLife. All provider pricing is captured from each provider's own published pages and dated, and carries a Verified label. Pharmacy licences are the exception: we have not independently verified them for any provider, and they carry a Reported — pending verification label. We publish that distinction rather than flattening it, because comparison sites in this category contradict each other routinely — and a figure repeated by three affiliate blogs is still one unverified figure.

We have not audited pharmacy licences. Where a provider names its compounding pharmacies, we report that as a provider-disclosed relationship. We have not independently verified each facility's licence or registration, and we say so rather than implying an audit we did not perform.

Advertised availability is not your availability. Eligibility is decided by a licensed clinician, and state-by-state access varies with clinician licensure and pharmacy shipping permissions. No page can promise you a price you will actually be offered.

We are commercially funded. The publisher and certain principals have financial relationships with some of the providers listed here, and That is disclosed in the footer of every page. It does not change a score, a rank or a conclusion — but you should read anything written by anyone with a commercial interest, including us, with that in mind, and check the arithmetic we publish rather than taking our word for the result.

Update history